Deutsche Bank analyst Amit Mehrotra maintains Landstar System (NASDAQ:LSTR) with a Hold and lowers the price target from $189 to $182.
Ultragenyx Plans To File For Accelerated Approval Of UX111 For The Treatment Of Sanfilippo Syndrome Type A, After Meeting With FDA
Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint for accelerated approval Data from existing clinical studies appear sufficient for a
